Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (43) 43
female (31) 31
male (30) 30
adult (26) 26
dermatology (24) 24
middle aged (22) 22
index medicus (21) 21
atopic dermatitis (16) 16
treatment outcome (14) 14
japan (12) 12
animals (11) 11
psoriasis (11) 11
psoriasis - drug therapy (9) 9
adolescent (8) 8
analysis (8) 8
severity of illness index (8) 8
aged (7) 7
calculating (7) 7
care and treatment (7) 7
computing (7) 7
counting (7) 7
dermatitis (7) 7
expression (7) 7
handling record carriers (7) 7
physics (7) 7
presentation of data (7) 7
recognition of data (7) 7
record carriers (7) 7
child (6) 6
pharmaceutical industry (6) 6
rheumatoid-arthritis (6) 6
adalimumab (5) 5
alleles (5) 5
allergy (5) 5
arthritis (5) 5
clinical trials (5) 5
dermatitis, atopic - drug therapy (5) 5
dermatitis, atopic - genetics (5) 5
dermatologic agents - adverse effects (5) 5
disease (5) 5
double-blind (5) 5
eczema (5) 5
hla (5) 5
immunology (5) 5
infliximab (5) 5
molecular sequence data (5) 5
monoclonal antibodies (5) 5
original (5) 5
original article (5) 5
patients (5) 5
polymerase chain reaction (5) 5
quality of life (5) 5
safety (5) 5
therapy (5) 5
tumor cells, cultured (5) 5
base sequence (4) 4
biochemistry (4) 4
cell biology (4) 4
corticosteroids (4) 4
dermatitis, atopic - immunology (4) 4
double-blind method (4) 4
further section (4) 4
genetic research (4) 4
genotype (4) 4
guidelines (4) 4
japanese (4) 4
management (4) 4
medical colleges (4) 4
mice (4) 4
molecular biology (4) 4
ointments (4) 4
original articles (4) 4
prescription drugs (4) 4
pruritus (4) 4
skin (4) 4
abridged index medicus (3) 3
adsorption (3) 3
adults (3) 3
agriculture, dairy & animal science (3) 3
anti-inflammatory agents - administration & dosage (3) 3
anti-inflammatory agents - adverse effects (3) 3
antibodies, monoclonal - adverse effects (3) 3
antibodies, monoclonal - therapeutic use (3) 3
antibodies, monoclonal, humanized - adverse effects (3) 3
antibodies, monoclonal, humanized - therapeutic use (3) 3
arthritis, psoriatic - drug therapy (3) 3
beef (3) 3
cattle (3) 3
cell movement - physiology (3) 3
dermatitis, atopic - blood (3) 3
dermatologic agents (3) 3
dermatologic agents - administration & dosage (3) 3
dermatologic agents - therapeutic use (3) 3
dermatology & venereal diseases (3) 3
diagnosis, differential (3) 3
drug therapy (3) 3
drug therapy, combination (3) 3
epinastine (3) 3
fda approval (3) 3
formulae, receipts, prescriptions (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial
by Blauvelt, Andrew, Dr and de Bruin-Weller, Marjolein, MD and Gooderham, Melinda, MD and Cather, Jennifer C, MD and Weisman, Jamie, MD and Pariser, David, Prof and Simpson, Eric L, Prof and Papp, Kim A, MD and Hong, H Chih-Ho, MD and Rubel, Diana, MD and Foley, Peter, MD and Prens, Errol, Prof and Griffiths, Christopher E M, Prof and Etoh, Takafumi, MD and Pinto, Pedro Herranz, MD and Pujol, Ramon M, MD and Szepietowski, Jacek C, Prof and Ettler, Karel, MD and KemĂŠny, Lajos, Prof and Zhu, Xiaoping, PhD and Akinlade, Bolanle, MD and Hultsch, Thomas, MD and Mastey, Vera, MS and Gadkari, Abhijit, PhD and Eckert, Laurent, PhD and Amin, Nikhil, MD and Graham, Neil M H, MD and Pirozzi, Gianluca, MD and Stahl, Neil, PhD and Yancopoulos, George D, MD and Shumel, Brad, MD
Lancet, The, ISSN 0140-6736, 2017, Volume 389, Issue 10086, pp. 2287 - 2303
Summary Background Dupilumab (an anti-interleukin-4-receptor-Îą monoclonal antibody) blocks signalling of interleukin 4 and interleukin 13, type 2/Th2 cytokines... 
Internal Medicine | DAILY PRACTICE COHORT | ADULT PATIENTS | DRUG SURVIVAL | MEDICINE, GENERAL & INTERNAL | CYCLOSPORINE-A | THERAPY | CLINICAL-TRIAL | ECZEMA | GUIDELINES | COATED MYCOPHENOLATE SODIUM | PERSISTENT ASTHMA | Severity of Illness Index | Double-Blind Method | Anti-Asthmatic Agents - therapeutic use | United States | Humans | Antibodies, Monoclonal - therapeutic use | Male | Treatment Outcome | Adrenal Cortex Hormones - therapeutic use | Dermatitis, Atopic - drug therapy | Injections, Subcutaneous | Adult | Female | Drug Therapy, Combination | Medical research | Medical colleges | Corticosteroids | Interleukins | Atopic dermatitis | Clinical trials | Monoclonal antibodies | Medicine, Experimental | Product development | Pharmaceutical industry | Analysis | Corticoids | Pathogenesis | Funding | Calcineurin | Interleukin | Calcineurin inhibitors | Lymphocytes T | Allergic diseases | Conjunctivitis | Immunoglobulin A | Dermatitis | Institutions | Acceptability | Interleukin 4 | Eczema | Skin diseases | Safety | Drug therapy | Signs and symptoms | Effectiveness | Cytokines | Dermatology | Cut-off | Abnormalities | Interleukin 13 | Management | Injection | Patients | Diseases | Asthma | Hospitals | Inhibitors | Interactive systems | Adults | Voice | Pharmaceuticals | Steroids
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Anti–Interleukin-31 Receptor A Antibody for Atopic Dermatitis
by Ruzicka, Thomas and Hanifin, Jon M and Furue, Masutaka and Pulka, Grazyna and Mlynarczyk, Izabela and Wollenberg, Andreas and Galus, Ryszard and Etoh, Takafumi and Mihara, Ryosuke and Yoshida, Hiroki and Stewart, Jonathan and Kabashima, Kenji and XCIMA Study Grp and XCIMA Study Group
The New England Journal of Medicine, ISSN 0028-4793, 03/2017, Volume 376, Issue 9, pp. 826 - 835
In a phase 2, placebo-controlled trial, nemolizumab, an antibody against interleukin-31 receptor A, reduced pruritus in patients with moderate-to-severe atopic... 
VISUAL ANALOG SCALE | ACTIGRAPHY | MEDICINE, GENERAL & INTERNAL | ITCH | ECZEMA | SUICIDAL IDEATION | PRURITUS | INTERLEUKIN-31 RECEPTOR | SKIN | T-CELLS | IL-31 | Antibodies, Monoclonal, Humanized - adverse effects | Receptors, Interleukin - immunology | Humans | Middle Aged | Male | Receptors, Interleukin - antagonists & inhibitors | Antibodies, Monoclonal, Humanized - administration & dosage | Dermatitis, Atopic - drug therapy | Pruritus - drug therapy | Intention to Treat Analysis | Adult | Female | Edema - chemically induced | Usage | Care and treatment | Interleukins | Atopic dermatitis | Diagnosis | Pruritus | Patients | Health aspects | Immunoglobulins | Cytokines | Body weight | Eczema | Clinical trials | Surface area | Drug therapy | Dermatitis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Clinical Practice Guidelines for the Management of Atopic Dermatitis 2016
by Saeki, Hidehisa and Nakahara, Takeshi and Tanaka, Akio and Kabashima, Kenji and Sugaya, Makoto and Murota, Hiroyuki and Ebihara, Tamotsu and Kataoka, Yoko and Aihara, Michiko and Etoh, Takafumi and Katoh, Norito and Comm Clinical Practice Guidelines and Committee for Clinical Practice Guidelines for the Management of Atopic Dermatitis of Japanese Dermatological Association
The Journal of Dermatology, ISSN 0385-2407, 10/2016, Volume 43, Issue 10, pp. 1117 - 1145
Atopic dermatitis (AD) is a disease characterized by relapsing eczema with pruritus as a primary lesion. Most patients have an atopic predisposition. The... 
evidence‐based medicine | clinical practice guideline | treatment | atopic dermatitis | diagnosis | evidence-based medicine | FLUTICASONE PROPIONATE CREAM | CONTROLLED-TRIAL | HOUSE-DUST-MITE | CHINESE HERBAL MEDICINE | 4-YEAR FOLLOW-UP | TACROLIMUS OINTMENT | OF-LIFE MEASURE | ACTIVATION-REGULATED CHEMOKINE | DERMATOLOGY | TOPICAL CORTICOSTEROIDS | DOUBLE-BLIND | Glucocorticoids - administration & dosage | Glucocorticoids - therapeutic use | Dermatologic Agents - administration & dosage | Humans | Immunosuppressive Agents - therapeutic use | Dermatitis, Atopic - classification | Dermatologic Agents - therapeutic use | Administration, Cutaneous | Dermatitis, Atopic - therapy | Histamine Antagonists - therapeutic use | Dermatologic Agents - adverse effects | Histamine Antagonists - adverse effects | Dermatitis, Atopic - diagnosis | Anti-Inflammatory Agents - adverse effects | Pruritus - therapy | Anti-Inflammatory Agents - therapeutic use | Anti-Inflammatory Agents - administration & dosage | Ointments | Glucocorticoids - adverse effects | Patient Education as Topic | Tacrolimus - administration & dosage | Severity of Illness Index | Administration, Oral | Japan | Histamine Antagonists - administration & dosage | Evidence-Based Medicine | Tacrolimus - adverse effects | Ultraviolet Therapy - methods | Tacrolimus - therapeutic use | Quality of Life | Diet Therapy - methods | Immunosuppressive Agents - adverse effects | Dermatitis, Atopic - blood | Patient Compliance | Usage | Tacrolimus | Dermatology | Atopic dermatitis | Formulae, receipts, prescriptions | Dermatologic agents | Pruritus | Prescription drugs | Clinical medicine | Dermatitis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Nemolizumab in patients with moderate-to-severe atopic dermatitis: Randomized, phase II, long-term extension study
by Kabashima, Kenji and Furue, Masutaka and Hanifin, Jon M and Pulka, Grazyna and Wollenberg, Andreas and Galus, Ryszard and Etoh, Takafumi and Mihara, Ryosuke and Nakano, Miwa and Ruzicka, Thomas
The Journal of Allergy and Clinical Immunology, ISSN 0091-6749, 10/2018, Volume 142, Issue 4, pp. 1121 - 1130.e7
Nemolizumab, an anti–IL-31 receptor A mAb, improved pruritus, dermatitis, and sleep in adults with moderate-to-severe atopic dermatitis that was inadequately... 
pruritus | atopic dermatitis | Monoclonal antibody | IL-31 receptor | nemolizumab | IL-31 | PLACEBO | MANAGEMENT | ECZEMA | GUIDELINES | NATIONAL-HEALTH | RECEPTOR | IMMUNOLOGY | INTERLEUKIN-31 | SKIN BARRIER | CARE | ALLERGY | Viral antibodies | Antibodies | Care and treatment | Pruritus | Atopic dermatitis | Analysis | Edema | FDA approval | Dermatitis | Patients | Asthma | Histamine | Randomization | Sleep | Eczema | Monoclonal antibodies | Population | Skin diseases | Skin | Adults | Safety | Drug dosages
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Oral tofacitinib efficacy, safety and tolerability in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis: A randomized, double‐blind, phase 3 study
by Asahina, Akihiko and Etoh, Takafumi and Igarashi, Atsuyuki and Imafuku, Shinichi and Saeki, Hidehisa and Shibasaki, Yoshiyuki and Tomochika, Yukiko and Toyoizumi, Shigeyuki and Nagaoka, Makoto and Ohtsuki, Mamitaro and study investigators and the study investigators
The Journal of Dermatology, ISSN 0385-2407, 08/2016, Volume 43, Issue 8, pp. 869 - 880
Tofacitinib is an oral Janus kinase inhibitor that is being investigated for psoriasis and psoriatic arthritis. Japanese patients aged 20 years or more with... 
plaque psoriasis | kinase inhibitor | psoriatic arthritis | Japan | tofacitinib | Plaque psoriasis | Tofacitinib | Kinase inhibitor | Psoriatic arthritis | RHEUMATOID-ARTHRITIS | MULTICENTER | PREVALENCE | INTERLEUKIN-12/23 MONOCLONAL-ANTIBODY | DERMATOLOGY | APREMILAST | THERAPY | JANUS KINASE INHIBITOR | HERPES-ZOSTER | PLACEBO-CONTROLLED TRIAL | CLINICAL-RESPONSE | Piperidines - administration & dosage | Herpes Zoster - etiology | Psoriasis - drug therapy | Double-Blind Method | Administration, Oral | Pyrimidines - administration & dosage | Humans | Middle Aged | Male | Treatment Outcome | Protein Kinase Inhibitors - adverse effects | Protein Kinase Inhibitors - administration & dosage | Pyrroles - administration & dosage | Arthritis, Psoriatic - drug therapy | Piperidines - adverse effects | Pyrimidines - adverse effects | Pyrroles - adverse effects | Adult | Female | Aged | Prescription drugs | Arthritis | Psoriasis | Pharmaceutical industry | Original
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: Efficacy and safety results from a Phase II/III randomized controlled study
by ASAHINA, Akihiko and NAKAGAWA, Hidemi and ETOH, Takafumi and OHTSUKI, Mamitaro and Adalimumab M04-688 Study Grp and Adalimumab M04-688 Study Group and THE ADALIMUMAB M04-688 STUDY GROUP
The Journal of Dermatology, ISSN 0385-2407, 04/2010, Volume 37, Issue 4, pp. 299 - 310
Incidence of psoriasis vulgaris in Asians is estimated at 0.05–0.3%. Studies in North America and Europe demonstrated that adalimumab, a fully human,... 
tumor necrosis factor antagonist | Japanese plaque psoriasis | adalimumab | Tumor necrosis factor antagonist | Adalimumab | TRIAL | PLACEBO | THERAPY | ARTHRITIS | DERMATOLOGY | Psoriasis - drug therapy | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Immunoglobulin G - therapeutic use | Antibodies, Monoclonal - therapeutic use | Male | Treatment Outcome | Antibodies, Monoclonal, Humanized | Anti-Inflammatory Agents - therapeutic use | Adult | Female | Asian Continental Ancestry Group - statistics & numerical data | Chronic Disease | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Monoclonal antibodies | Immunoglobulin G
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Japanese guidance for use of biologics for psoriasis (the 2013 version)
by Ohtsuki, Mamitaro and Terui, Tadashi and Ozawa, Akira and Morita, Akimichi and Sano, Shigetoshi and Takahashi, Hidetoshi and Komine, Mayumi and Etoh, Takafumi and Igarashi, Atsuyuki and Torii, Hideshi and Asahina, Akihiko and Nemoto, Osamu and Nakagawa, Hidemi and Japanese Dermatological Assoc and Biologics Review Committee of the Japanese Dermatological Association and The Biologics Review Committee of the Japanese Dermatological Association: Chair: Hidemi Nakagawa
The Journal of Dermatology, ISSN 0385-2407, 09/2013, Volume 40, Issue 9, pp. 683 - 695
The clinical use of adalimumab and infliximab, human anti‐tumor necrosis factor (TNF)‐α monoclonal antibodies, for psoriasis began in January 2010. In January... 
ustekinumab | biologics | guidance | infliximab | psoriasis | adalimumab | MANAGEMENT | PLAQUE PSORIASIS | GUIDELINES | ARTHRITIS | CARE | DERMATOLOGY | Animals | Antibodies, Monoclonal, Humanized - therapeutic use | Psoriasis - drug therapy | Humans | Patient Safety | Drug Therapy, Combination | Contraindications | Patient Selection | Psoriasis | Monoclonal antibodies | Usage | Drug therapy | Pharmaceutical industry | Drugs
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Adalimumab treatment optimization for psoriasis: Results of a long‐term phase 2/3 Japanese study
by Asahina, Akihiko and Ohtsuki, Mamitaro and Etoh, Takafumi and Gu, Yihua and Okun, Martin M and Teixeira, Henrique D and Yamaguchi, Yuji and Nakagawa, Hidemi
The Journal of Dermatology, ISSN 0385-2407, 11/2015, Volume 42, Issue 11, pp. 1042 - 1052
The tumor necrosis factor‐α inhibitor, adalimumab, is approved to treat moderate‐to‐severe plaque psoriasis (40 mg every‐other‐week or 80 mg every‐other‐week... 
Japanese patients | long‐term treatment | psoriasis | adalimumab | 80 mg | long-term treatment | 80 mg | RHEUMATOID-ARTHRITIS | RANDOMIZED CONTROLLED-TRIALS | MODERATE | METAANALYSIS | EFFICACY | SAFETY | 80mg | OPEN-LABEL | INTERLEUKIN-12/23 MONOCLONAL-ANTIBODY | DERMATOLOGY | CHRONIC PLAQUE PSORIASIS | DOUBLE-BLIND | Double-Blind Method | Humans | Japan | Middle Aged | Male | Adalimumab - adverse effects | Self Administration | Adalimumab - administration & dosage | Anti-Inflammatory Agents - adverse effects | Adult | Anti-Inflammatory Agents - administration & dosage | Female | Psoriasis - therapy | Clinical trials
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Therapeutic depletion of myeloid lineage leukocytes in patients with generalized pustular psoriasis indicates a major role for neutrophils in the immunopathogenesis of psoriasis
by Ikeda, Shigaku, MD and Takahashi, Hidetoshi, MD and Suga, Yasushi, MD and Eto, Hikaru, MD and Etoh, Takafumi, MD and Okuma, Keiko, MD and Takahashi, Kazuo, MD and Kanbara, Takeshi, MD and Seishima, Mariko, MD and Morita, Akimichi, MD and Imai, Yasutomo, MD and Kanekura, Takuro, MD
Journal of the American Academy of Dermatology, ISSN 0190-9622, 2012, Volume 68, Issue 4, pp. 609 - 617
Background Generalized pustular psoriasis (GPP) is a chronic autoimmune disease characterized by fever, erythema, and neutrophilic pustules over large areas of... 
Dermatology | granulocytapheresis | granulocyte and monocyte adsorption apheresis | edema | generalized pustular psoriasis | granulocytes and monocytes | Dermatology Life Quality Index | erythroderma | neutrophilic pustules | CROHNS-DISEASE | INTERLEUKIN-1 RECEPTOR ANTAGONIST | HEPATOCYTE GROWTH-FACTOR | NECROSIS-FACTOR-ALPHA | DERMATOLOGY | PROINFLAMMATORY CD14(+)CD16(+)DR(++) MONOCYTES | INFLAMMATORY-BOWEL-DISEASE | INTENSIVE GRANULOCYTE | ACTIVE ULCERATIVE-COLITIS | MONOCYTE ADSORPTION APHERESIS | POLYMORPHONUCLEAR NEUTROPHILS | Leukocytes - immunology | Psoriasis - immunology | Leukocyte Reduction Procedures | Psoriasis - pathology | Humans | Middle Aged | Adult | Female | Male | Aged | Psoriasis - therapy | Medical colleges | Care and treatment | Psoriasis | Health aspects | Retinoids | Adsorption
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Atopic dermatitis disease registry in Japanese adult patients with moderate to severe atopic dermatitis (ADDRESS‐J): Baseline characteristics, treatment history and disease burden
by Katoh, Norito a